Application of M-cell targeting ligand Co4B enhances Ag-specific mucosal and systemic immunity and protection against MERS-CoV infection after intranasal immunization

Abstract

Abstract Middle East respiratory syndrome is associated with severe pneumonia and poses a global public health threat. Authorized vaccines against the causative agent of MERS-CoV are urgently needed. In order to optimize the efficacy of recombinant vaccines, adjuvants should be required. Therefore, we previously identified a ligand Co4B as an adjuvant to enhance Ag delivery to the nasal mucosa immune compartment and promote Ag-specific mucosal and systemic immune responses via intranasal administration against A. pleuropneumoniae infection in a murine model. Based on the pathogenesis of MERS-CoV which infects host following respiratory route; thus, we generated a recombinant protein conjugated with Co4B to the MERS-CoV spike protein receptor-binding domain (S-RBD) to develop mucosal subunit vaccine candidate. Ag-specific mucosal IgA and systemic IgG antibody responses, together with virus-neutralizing capacities, were highly elicited in C57BL/6 and human dipeptidyl peptidase 4-transgenic (hDPP4-Tg) mice intranasally immunized with Co4B-conjugated S-RBD compared to those immunized with originally S-RBD. Ag-specific T cell-mediated immunity was also induced in the spleen and lungs of mice intranasally immunized with Co4B-conjugated S-RBD. Intranasal immunization of hDPP4-Tg mice with Co4B-conjugated S-RBD prominently reduced immune cell infiltration into the tissues of virus-challenged mice. Finally, Co4B-conjugated S-RBD-immunized mice demonstrated were improved protection against infection, more likely to survive, and exhibited less body weight loss. Collectively, our results suggest that Co4B-conjugated S-RBD could be used as an improved subunit vaccine candidate against MERS-CoV infection. This work was supported by the Ministry of Science and ICT No. 2020K1A4A7A02095058 and the NRF funded by the Ministry of Education No. 2019R1I1A3A01062224. Ms. Y. L. Yang and Ms. B.-H. Cho were supported by the BK21 FOUR program of the Department of Bioactive Material Sciences.